ImmunityBio, Inc. Stock Prediction and Forecast [IBRX]

AI-generated source summary

The stock IBRX is showing a strong bullish trend based on technical indicators. The 50-day moving average is at $167.08 and the 200-day moving average is at $152.36, with the current price above both, signaling bullishness. Volume at the last close was 99.01 million, higher than average, indicating increased investor interest. Fundamental analysis shows earnings per share at $5.89 and a P/E ratio of 30.09, suggesting consistent growth and a fair valuation. The stock experienced significant volatility, with a 52-week low of $124.17 and a high of $179.35. The stock is currently trading at $6.46, with a target of $7.37, and a fail bound at $6.37. A breach below $6.37 would invalidate the bullish short-term outlook. The long-term forecast suggests a potential change of -5.5% to 5.51% over the next 12 months. The stock has shown resilience, with a buy signal from the 3-month MACD. However, some negative signals from pivot points suggest potential near-term volatility.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   24 Jan 2026, 03:56 UTC

   The analyst published the original source item.

2. First prediction resolved

   26 Jan 2026, 14:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   26 Jan 2026, 14:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:11 UTC

   Tahlil Plus began monitoring the extracted predictions.